BR0314486A - Composição farmacêutica de sais anfetamìnicos com liberação sustentada e método para o tratamento do distúrbio de déficit de atenção e hiperatividade - Google Patents

Composição farmacêutica de sais anfetamìnicos com liberação sustentada e método para o tratamento do distúrbio de déficit de atenção e hiperatividade

Info

Publication number
BR0314486A
BR0314486A BR0314486-0A BR0314486A BR0314486A BR 0314486 A BR0314486 A BR 0314486A BR 0314486 A BR0314486 A BR 0314486A BR 0314486 A BR0314486 A BR 0314486A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
treatment
sustained release
attention deficit
hyperactivity disorder
Prior art date
Application number
BR0314486-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Richard Couch
Beth Burnside
Rong-Kun Chang
Original Assignee
Shire Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31996998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0314486(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Lab Inc filed Critical Shire Lab Inc
Publication of BR0314486A publication Critical patent/BR0314486A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BR0314486-0A 2002-09-24 2003-09-24 Composição farmacêutica de sais anfetamìnicos com liberação sustentada e método para o tratamento do distúrbio de déficit de atenção e hiperatividade BR0314486A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41279902P 2002-09-24 2002-09-24
US10/353,073 US6913768B2 (en) 2002-09-24 2003-01-29 Sustained release delivery of amphetamine salts
PCT/US2003/029757 WO2004028509A1 (en) 2002-09-24 2003-09-24 Sustained released delivery of amphetamine salts

Publications (1)

Publication Number Publication Date
BR0314486A true BR0314486A (pt) 2005-08-02

Family

ID=31996998

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314486-0A BR0314486A (pt) 2002-09-24 2003-09-24 Composição farmacêutica de sais anfetamìnicos com liberação sustentada e método para o tratamento do distúrbio de déficit de atenção e hiperatividade

Country Status (29)

Country Link
US (2) US6913768B2 (enExample)
EP (1) EP1542660B1 (enExample)
JP (1) JP2006503071A (enExample)
KR (1) KR20050084589A (enExample)
CN (1) CN1684668B (enExample)
AP (1) AP2030A (enExample)
AT (1) ATE495731T1 (enExample)
AU (1) AU2003272619B2 (enExample)
BR (1) BR0314486A (enExample)
CA (1) CA2499546C (enExample)
CR (1) CR7766A (enExample)
CY (1) CY1112335T1 (enExample)
DE (1) DE60335807D1 (enExample)
DK (1) DK1542660T3 (enExample)
EA (1) EA018082B1 (enExample)
EC (1) ECSP055702A (enExample)
ES (1) ES2360046T3 (enExample)
HR (1) HRP20050356A2 (enExample)
IL (1) IL167470A (enExample)
IS (1) IS2814B (enExample)
MA (1) MA27469A1 (enExample)
MX (1) MXPA05003129A (enExample)
NO (1) NO336938B1 (enExample)
NZ (1) NZ539216A (enExample)
OA (1) OA13075A (enExample)
PL (1) PL375991A1 (enExample)
SI (1) SI1542660T1 (enExample)
WO (1) WO2004028509A1 (enExample)
ZA (1) ZA200502406B (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
ATE372112T1 (de) * 2003-02-10 2007-09-15 Shire Biochem Inc Enantiomere amphetamine enthaltende zusammensetzungen zur behandlung von aufmerksamkeitsdefizit-/hyperaktivitätsstörung (adhd)
EP2204168B1 (en) 2003-04-07 2015-01-14 Supernus Pharmaceuticals, Inc. Once daily formulations of tetracyclines
SI1644019T2 (en) * 2003-05-29 2018-04-30 Shire Llc AMPHETAMINE COMPOUNDS COMPOUNDS TO ABUSE
BRPI0318456B8 (pt) * 2003-08-08 2021-05-25 Biovail Laboratories Int Srl tablete com liberação modificada
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
MX2007006120A (es) 2004-11-23 2007-12-07 Adamas Pharmaceuticals Inc Metodo y composicion para administrar a un sujeto un antagonista del receptor de nmda.
EP1845968A2 (en) 2004-11-24 2007-10-24 Neuromolecular Pharmaceuticals, Inc Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
JP2008535837A (ja) * 2005-04-06 2008-09-04 マリンクロッド・インコーポレイテッド マトリックスをベースとするパルス放出製剤
RU2007140348A (ru) 2005-04-06 2009-05-20 Адамас Фармасьютикалс, Инк. (Us) Способы и композиции для лечения заболеваний цнс
KR101495146B1 (ko) 2006-03-16 2015-02-24 트리스 파마 인코포레이티드 약물 - 이온교환 수지 복합체를 함유하는 변형 방출 제제
AU2007238858A1 (en) * 2006-04-10 2007-10-25 Shire Llc Mono and di-substituted oxycodone compounds and compositions
US20070253927A1 (en) * 2006-04-13 2007-11-01 Gwenaelle Jegou Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
WO2007120864A2 (en) * 2006-04-14 2007-10-25 Shire Llc Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
EP2023900B1 (en) * 2006-05-12 2014-12-24 Shire LLC Controlled dose drug delivery system
KR100774613B1 (ko) * 2006-05-26 2007-11-12 한국화학연구원 수불용성 고분자로 이루어진 서방형 약물 전달체
US20080075768A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophobic opioid abuse deterrent delivery system using opioid antagonists
US20080090771A1 (en) * 2006-10-06 2008-04-17 Shire Llc Abuse-resistant hydrocodone compounds, compositions and methods of using the same
US20080207668A1 (en) * 2006-10-06 2008-08-28 New River Pharmaceuticals Inc. Pharmaceutical compositions of hydromorphone for prevention of overdose or abuse
JP2010522135A (ja) * 2006-10-09 2010-07-01 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
US20100104621A1 (en) * 2007-02-21 2010-04-29 Connected Health Systems, Llc Treating adhd and other diseases involving inflammation
US20080268047A1 (en) * 2007-04-24 2008-10-30 Xavier University Of Louisiana Controlled Release Multiple Layer Coatings
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
JP2011513391A (ja) * 2008-03-05 2011-04-28 パナセア バイオテック リミテッド ミコフェノラートを含有する徐放性医薬組成物およびその方法
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
GB201002612D0 (en) * 2010-02-16 2010-03-31 Jagotec Ag Improvements in or relating to organic compounds
WO2011133980A1 (en) 2010-04-23 2011-10-27 Subhash Desai Therapeutic formulation for reduced drug side effects
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
EP4316488A3 (en) * 2011-03-23 2024-02-28 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
EP2726066B1 (en) 2011-06-28 2021-03-31 Neos Therapeutics, LP Dosage forms of amphetamine for oral administration
WO2013059676A1 (en) 2011-10-21 2013-04-25 Subhash Desai Compositions for reduction of side effects
ES2717469T3 (es) 2012-08-15 2019-06-21 Tris Pharma Inc Comprimido masticable de metilfenidato de liberación prolongada
US20140100249A1 (en) 2012-10-09 2014-04-10 Douglas Sears Therapeutic Treatment
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US10973783B2 (en) 2015-12-30 2021-04-13 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN117860718A (zh) 2017-08-24 2024-04-12 阿达玛斯药物有限责任公司 金刚烷胺组合物、其制备和使用方法
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
AU2020231916B2 (en) 2019-03-01 2025-08-28 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB768512A (en) 1954-08-16 1957-02-20 Smith Kline & French Internat Improvements in or relating to pharmaceutical tablets
US4049791A (en) * 1974-06-21 1977-09-20 Delco Chemical Company, Inc. Prolonged acting appetite suppressant and anti-obesity compositions containing amphetamine adipate, dextroamphetamine adipate, amphetamine sulfate and dextroamphetamine sulfate as the active agents
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
US5002776A (en) * 1983-12-22 1991-03-26 Elan Corporation, Plc Controlled absorption diltiazem formulations
US4917899A (en) * 1983-12-22 1990-04-17 Elan Corporation Plc Controlled absorption diltiazem formulation
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
WO1987000044A1 (en) 1985-07-02 1987-01-15 The Upjohn Company Therapeutic formulations with bimodal release characteristics
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
DE3678644D1 (de) 1985-08-16 1991-05-16 Procter & Gamble Wirkstoffpartikel mit sowohl kontinuierlicher als auch schneller freisetzung.
JPS62103012A (ja) * 1985-10-23 1987-05-13 Eisai Co Ltd 多重顆粒
JPH0778017B2 (ja) * 1985-12-28 1995-08-23 住友製薬株式会社 パルス的かつ持続放出性製剤
US4723958A (en) * 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
DE3712095A1 (de) * 1987-04-10 1988-10-20 Lentia Gmbh Bindemittelfreies granulat mit verzoegerter wirkstoffabgabe
DE3827214A1 (de) * 1988-08-11 1990-02-15 Roehm Gmbh Retardierte arzneiform und verfahren zu ihrer herstellung
US5275819A (en) * 1989-02-06 1994-01-04 Amer Particle Technologies Inc. Drug loaded pollen grains with an outer coating for pulsed delivery
EP0458887A1 (en) 1989-02-16 1991-12-04 Btg International Limited Dispensing device
FI920856A0 (fi) * 1989-08-28 1992-02-26 Pharmaceutical Delivery System Bioeroderbar polymerer foer kontrollerad frigoerelse av terapeutiska aemnen.
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5232705A (en) * 1990-08-31 1993-08-03 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
ZA92543B (en) * 1991-01-30 1992-10-28 Alza Corp Osmotic device for delayed delivery of agent
US5226902A (en) * 1991-07-30 1993-07-13 University Of Utah Pulsatile drug delivery device using stimuli sensitive hydrogel
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5308348A (en) * 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
EP0653935B1 (en) * 1992-08-05 2002-05-08 F.H. FAULDING & CO. LIMITED Pelletised pharmaceutical composition
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
US5395626A (en) * 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5582855A (en) * 1994-07-01 1996-12-10 Fuisz Technologies Ltd. Flash flow formed solloid delivery systems
FR2723536A1 (fr) * 1994-08-11 1996-02-16 Seth Pawan Composition permettant une liberation selective d'un principe actif
US5731314A (en) * 1995-01-06 1998-03-24 Bencherif; Merouane Pharamceutical compositions for prevention and treatment of tourette's syndrome
JPH11509227A (ja) 1995-07-14 1999-08-17 カイロサイエンス・リミテッド ｄ−トレオ−メチルフェニデートの治療的使用
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US6210705B1 (en) 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US5945123A (en) * 1998-04-02 1999-08-31 K-V Pharmaceutical Company Maximizing effectiveness of substances used to improve health and well being
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6322819B1 (en) 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
PL205109B1 (pl) * 1998-11-02 2010-03-31 Elan Pharma Int Ltd Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
WO2000059481A1 (en) * 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
US6384020B1 (en) * 1999-07-14 2002-05-07 Shire Laboratories, Inc. Rapid immediate release oral dosage form
EP2319540A1 (en) * 2002-02-22 2011-05-11 Shire LLC Sustained release pharmaceutical compounds to prevent abuse of controlled substances
ATE372112T1 (de) * 2003-02-10 2007-09-15 Shire Biochem Inc Enantiomere amphetamine enthaltende zusammensetzungen zur behandlung von aufmerksamkeitsdefizit-/hyperaktivitätsstörung (adhd)
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system

Also Published As

Publication number Publication date
EA200500530A1 (ru) 2005-10-27
CN1684668B (zh) 2010-05-26
WO2004028509A1 (en) 2004-04-08
EP1542660B1 (en) 2011-01-19
MA27469A1 (fr) 2005-08-01
AP2005003275A0 (en) 2005-06-30
IS7818A (is) 2005-04-22
US20040059002A1 (en) 2004-03-25
CN1684668A (zh) 2005-10-19
EP1542660A1 (en) 2005-06-22
MXPA05003129A (es) 2005-10-05
CA2499546C (en) 2008-05-20
NO336938B1 (no) 2015-11-30
SI1542660T1 (sl) 2011-06-30
ZA200502406B (en) 2005-10-04
NO20051986L (no) 2005-06-24
ATE495731T1 (de) 2011-02-15
US6913768B2 (en) 2005-07-05
DE60335807D1 (de) 2011-03-03
NZ539216A (en) 2008-02-29
KR20050084589A (ko) 2005-08-26
OA13075A (en) 2006-11-10
AU2003272619B2 (en) 2008-10-09
CY1112335T1 (el) 2015-12-09
CR7766A (es) 2007-07-10
DK1542660T3 (da) 2011-05-16
PL375991A1 (en) 2005-12-12
CA2499546A1 (en) 2004-04-08
ES2360046T3 (es) 2011-05-31
EA018082B1 (ru) 2013-05-30
AP2030A (en) 2009-08-24
US20050158384A1 (en) 2005-07-21
NO20051986D0 (no) 2005-04-22
HRP20050356A2 (en) 2005-10-31
JP2006503071A (ja) 2006-01-26
ECSP055702A (es) 2006-01-27
HK1075828A1 (en) 2005-12-30
IS2814B (is) 2012-11-15
AU2003272619A1 (en) 2004-04-19
IL167470A (en) 2010-06-30

Similar Documents

Publication Publication Date Title
BR0314486A (pt) Composição farmacêutica de sais anfetamìnicos com liberação sustentada e método para o tratamento do distúrbio de déficit de atenção e hiperatividade
BRPI0519195A2 (pt) composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal
BRPI0609711B8 (pt) uso de uma solução aquosa com potencial redutivo oxidativo (orp)
BR0316906A (pt) administração do capsaicinoides
BR0311126A (pt) Composições e método para tratar infecção em gado bovino e em suìnos
AR043670A1 (es) Composicion farmaceutica que contiene lactato y usos de la misma
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
ECSP055739A (es) Anticuerpos de neutralización contra gdf-8, y sus usos
BRPI0610901A2 (pt) mÉtodo de uso de uma soluÇço aquosa de potencial oxi-redutivo em aplicaÇÕes dentais
BRPI0615157A2 (pt) composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto
CR8380A (es) Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos
MY146351A (en) Compositions for treating infection in cattle and swine
NO20082679L (no) Sammensetning og fremgangsmate for a behandle CNS lidelser
ECSP034617A (es) Kit de repinotan
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BRPI0402659A (pt) Uso de células tronco, método de engenharia tecidual, usos de tecidos dentais e substituto biológico do dente
BRPI0416933A (pt) composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e, métodos para aumentar a respiração mitocondrial em um paciente, e para reduzir a quantidade de espécies de oxigênio reativas em um paciente
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
Gevorgyan et al. Radiation effects and radioprotection in MC3T3-E1 mouse calvarial osteoblastic cells
ATE429826T1 (de) Zusammensetzung zur prävention und/oder behandlung von verändertem knochenmetabolismus
BRPI0416706A (pt) composições farmacêuticas para o tratamento da disfunção, doença ou distúrbio renal, em particular em recipientes diabéticos
BRPI0606898A2 (pt) uso de agonista de 5-ht4 na preparação de medicamentos e método útil no esvaziamento gástrico retardado
Riyat et al. An experimental study of the effect of strontium pre-treatment on calcium release from carious and non-carious teeth
BRPI0418122A (pt) formulação farmacêutica de liberação controlada

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SHIRE LLC (US)

Free format text: TRANSFERIDO POR FUSAO DE: SHIRE LABORATORIES, INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 31/137, A61K 31/205, A61K 9/22, A61K 9/50, A61K 9/54, A61K 31/137, A61K 31/185, A61K 9/22, A61K 9/50, A61P 9/52, A61P 25/00, A61P 43/00

Ipc: A61K 9/22 (2011.01), A61K 31/137 (2011.01), A61K 9

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL